Clinical Trial

Elacestrant in Advanced Triple Positive Breast Cancer

Name: Elacestrant in Advanced Triple Positive Breast Cancer — clinical trial record (NCT07612215)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study to assess the safety and efficacy of elacestrant, a selective estrogen receptor degrader (SERD) and dual biologic therapy, trastuzumab and pertuzumab, in patients with triple-positive breast cancer with and without an ESR1 mutation.

Trial Details

NCT Number	NCT07612215
Lead Sponsor	NYU Langone Health
Conditions	ER Positive, HER2 Positive Breast Cancer
Enrollment	50 participants
Start Date	2026-05-13
Primary Completion	2029-05 (estimated)
Study Completion	2030-05 (estimated)
Updated on ClinicalTrials.gov	2026-05-28